Questions Submission Form for Endpoint Considerations to Facilitate Drug Development on Niemann-Pick Type C (NPC): Key Themes and Future Directions from the January 2022 Public Workshop
In January 2022, the Duke-Margolis Center for Health Policy and the U.S. Food and Drug Administration (FDA) convened a group of experts to discuss clinical endpoints relevant to clinical trials and innovative measurement strategies with the overall goal of supporting the development of safe and effective treatments for those living with NPC. Duke-Margolis Center will hold a follow-up webinar on August 4, 2022, which will provide an overview of the key themes and future directions shared during the January 2022 workshop and presented in the recently released workshop summary report.
If you have a question you would like to submit for consideration during this webinar, you may submit using the form below.
